vs
Side-by-side financial comparison of GREENE COUNTY BANCORP INC (GCBC) and GYRE THERAPEUTICS, INC. (GYRE). Click either name above to swap in a different company.
GYRE THERAPEUTICS, INC. is the larger business by last-quarter revenue ($37.2M vs $22.2M, roughly 1.7× GREENE COUNTY BANCORP INC). GREENE COUNTY BANCORP INC runs the higher net margin — 46.3% vs -3.7%, a 50.0% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs 23.8%). GREENE COUNTY BANCORP INC produced more free cash flow last quarter ($6.2M vs $-5.8M). Over the past eight quarters, GREENE COUNTY BANCORP INC's revenue compounded faster (18.9% CAGR vs 17.0%).
Bank of Greene County is an American federally-chartered savings bank headquartered in Catskill, NY. The bank's branches are located in the Upstate New York counties of Greene, Columbia, Albany, Ulster, and Rensselaer.
GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.
GCBC vs GYRE — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $22.2M | $37.2M |
| Net Profit | $10.3M | $-1.4M |
| Gross Margin | — | 95.3% |
| Operating Margin | 52.0% | 0.3% |
| Net Margin | 46.3% | -3.7% |
| Revenue YoY | 23.8% | 33.4% |
| Net Profit YoY | 37.4% | -340.1% |
| EPS (diluted) | $0.60 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $22.2M | $37.2M | ||
| Q3 25 | $21.5M | $30.6M | ||
| Q2 25 | $20.5M | $26.8M | ||
| Q1 25 | $20.1M | $22.1M | ||
| Q4 24 | $17.9M | $27.9M | ||
| Q3 24 | $16.9M | $25.5M | ||
| Q2 24 | $16.6M | $25.2M | ||
| Q1 24 | $15.7M | $27.2M |
| Q4 25 | $10.3M | $-1.4M | ||
| Q3 25 | $8.9M | $5.9M | ||
| Q2 25 | $9.3M | $1.6M | ||
| Q1 25 | $8.1M | $3.7M | ||
| Q4 24 | $7.5M | $569.0K | ||
| Q3 24 | $6.3M | $2.9M | ||
| Q2 24 | $6.7M | $4.5M | ||
| Q1 24 | $5.9M | $9.9M |
| Q4 25 | — | 95.3% | ||
| Q3 25 | — | 94.7% | ||
| Q2 25 | — | 95.7% | ||
| Q1 25 | — | 95.9% | ||
| Q4 24 | — | 95.8% | ||
| Q3 24 | — | 96.2% | ||
| Q2 24 | — | 96.9% | ||
| Q1 24 | — | 96.4% |
| Q4 25 | 52.0% | 0.3% | ||
| Q3 25 | 47.4% | 22.7% | ||
| Q2 25 | 53.5% | 8.1% | ||
| Q1 25 | 44.6% | 10.3% | ||
| Q4 24 | 45.0% | 2.4% | ||
| Q3 24 | 39.6% | 16.6% | ||
| Q2 24 | 41.2% | 12.7% | ||
| Q1 24 | 39.4% | 29.7% |
| Q4 25 | 46.3% | -3.7% | ||
| Q3 25 | 41.2% | 19.4% | ||
| Q2 25 | 45.6% | 5.9% | ||
| Q1 25 | 40.1% | 16.9% | ||
| Q4 24 | 41.7% | 2.0% | ||
| Q3 24 | 37.1% | 11.2% | ||
| Q2 24 | 40.6% | 18.0% | ||
| Q1 24 | 37.3% | 36.6% |
| Q4 25 | $0.60 | $-0.01 | ||
| Q3 25 | $0.52 | $0.03 | ||
| Q2 25 | $0.55 | $0.00 | ||
| Q1 25 | $0.47 | $0.00 | ||
| Q4 24 | $0.44 | $0.00 | ||
| Q3 24 | $0.37 | $0.01 | ||
| Q2 24 | $0.39 | $0.01 | ||
| Q1 24 | $0.34 | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $52.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $258.3M | $106.0M |
| Total Assets | $3.1B | $166.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $52.4M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $54.4M | ||
| Q1 25 | $155.5M | $29.9M | ||
| Q4 24 | $166.4M | $26.7M | ||
| Q3 24 | — | $25.1M | ||
| Q2 24 | $190.4M | $25.1M | ||
| Q1 24 | — | $37.4M |
| Q4 25 | $258.3M | $106.0M | ||
| Q3 25 | $248.2M | $101.9M | ||
| Q2 25 | $238.8M | $92.0M | ||
| Q1 25 | $229.0M | $68.1M | ||
| Q4 24 | $218.4M | $63.3M | ||
| Q3 24 | $216.3M | $63.2M | ||
| Q2 24 | $206.0M | $60.4M | ||
| Q1 24 | $199.2M | $56.6M |
| Q4 25 | $3.1B | $166.1M | ||
| Q3 25 | $3.1B | $159.4M | ||
| Q2 25 | $3.0B | $152.6M | ||
| Q1 25 | $3.0B | $129.8M | ||
| Q4 24 | $3.0B | $125.4M | ||
| Q3 24 | $2.9B | $125.2M | ||
| Q2 24 | $2.8B | $120.9M | ||
| Q1 24 | $2.9B | $122.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $6.4M | $-5.6M |
| Free Cash FlowOCF − Capex | $6.2M | $-5.8M |
| FCF MarginFCF / Revenue | 28.0% | -15.5% |
| Capex IntensityCapex / Revenue | 0.9% | 0.4% |
| Cash ConversionOCF / Net Profit | 0.62× | — |
| TTM Free Cash FlowTrailing 4 quarters | $47.3M | $-180.0K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.4M | $-5.6M | ||
| Q3 25 | $7.0M | $4.7M | ||
| Q2 25 | $28.0M | $2.1M | ||
| Q1 25 | $7.3M | $-129.0K | ||
| Q4 24 | $5.3M | $-2.8M | ||
| Q3 24 | $2.1M | $1.7M | ||
| Q2 24 | $24.9M | $-5.5M | ||
| Q1 24 | $5.6M | $2.9M |
| Q4 25 | $6.2M | $-5.8M | ||
| Q3 25 | $6.5M | $4.0M | ||
| Q2 25 | $27.3M | $1.8M | ||
| Q1 25 | $7.3M | $-251.0K | ||
| Q4 24 | $5.1M | $-2.8M | ||
| Q3 24 | $2.0M | $1.0M | ||
| Q2 24 | $23.4M | $-6.9M | ||
| Q1 24 | $4.9M | $2.7M |
| Q4 25 | 28.0% | -15.5% | ||
| Q3 25 | 30.4% | 13.1% | ||
| Q2 25 | 133.3% | 6.8% | ||
| Q1 25 | 36.1% | -1.1% | ||
| Q4 24 | 28.6% | -10.1% | ||
| Q3 24 | 11.8% | 4.1% | ||
| Q2 24 | 141.2% | -27.5% | ||
| Q1 24 | 31.3% | 9.8% |
| Q4 25 | 0.9% | 0.4% | ||
| Q3 25 | 1.9% | 2.2% | ||
| Q2 25 | 3.4% | 1.0% | ||
| Q1 25 | 0.3% | 0.6% | ||
| Q4 24 | 1.0% | 0.2% | ||
| Q3 24 | 0.9% | 2.7% | ||
| Q2 24 | 9.1% | 5.8% | ||
| Q1 24 | 4.2% | 0.9% |
| Q4 25 | 0.62× | — | ||
| Q3 25 | 0.78× | 0.79× | ||
| Q2 25 | 3.00× | 1.32× | ||
| Q1 25 | 0.91× | -0.03× | ||
| Q4 24 | 0.71× | -4.85× | ||
| Q3 24 | 0.34× | 0.60× | ||
| Q2 24 | 3.70× | -1.21× | ||
| Q1 24 | 0.95× | 0.29× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
